{
  "schemaVersion": 1,
  "id": "research-040",
  "slug": "040-how-the-diabetes-trial-separated-symptoms-from-glucose-markers",
  "title": "How the diabetes trial separated symptoms from glucose markers",
  "catalogLabel": "ARA-290",
  "productCollection": "https://heritagebiolabs.com/research-library/products/ara-290",
  "productHandles": [
    "ara-290-703"
  ],
  "productUrls": [
    "https://heritagebiolabs.com/product/ara-290-703"
  ],
  "readingFocus": "Interpreting evidence",
  "readingFocusNote": "Reading focus is a navigational tag, not an evidence grade.",
  "wordCount": 282,
  "sourceYears": [
    2008,
    2015
  ],
  "paragraphs": [
    "Peptide bonds link amino acids into short chains called peptides. The order of the amino acids can give a peptide a surface that interacts with cell signaling machinery. ARA-290 is an experimental 11-amino-acid peptide designed from erythropoietin to study tissue responses without reproducing its red-blood-cell stimulus. An older randomized trial in people with type 2 diabetes and painful neuropathy asked whether the peptide changed symptoms or measures of metabolic control. [1] [2]",
    "The investigators compared ARA-290 with placebo and collected several different types of data. The PainDetect questionnaire asks about features of symptoms associated with nerve pain. A blood test called HbA1c reflects average glucose exposure over a longer period than a single glucose reading. Imaging of small nerves in the cornea gave the trial a separate structural measure. These measures let the team ask whether changes were visible in several domains of the same illness. [1]",
    "The researchers reported a difference in the PainDetect score favoring ARA-290 and a change in HbA1c. They also explored a subset with lower corneal nerve fiber density at the start. In that subset, the relationship between changes in the nerve measure and symptom score was stronger in the peptide group. A subgroup finding can suggest a question for a future trial. A prespecified comparison in an independent sample would give greater confidence about who responds and why. [1]",
    "A questionnaire difference over a brief study period describes how participants answered during that study. It provides limited information about whether a change persists, whether underlying nerve damage slows, or whether other populations experience a similar result. A glucose marker and a symptom measure also cannot establish which changed first or whether one caused the other. [1]"
  ],
  "sources": [
    {
      "number": 1,
      "citation": "Michael Brines et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular Medicine (publication 2015-03-13).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/25387363/"
    },
    {
      "number": 2,
      "citation": "Michael Brines et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proceedings of the National Academy of Sciences (publication 2008-08-01).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/18676614/"
    }
  ],
  "canonicalUrl": "https://heritagebiolabs.com/research-library/articles/040-how-the-diabetes-trial-separated-symptoms-from-glucose-markers",
  "markdownUrl": "https://heritagebiolabs.com/research-library/data/articles/040-how-the-diabetes-trial-separated-symptoms-from-glucose-markers.md",
  "jsonUrl": "https://heritagebiolabs.com/research-library/data/articles/040-how-the-diabetes-trial-separated-symptoms-from-glucose-markers.json",
  "provenance": {
    "sourceArchive": "Peptide Research Articles - All 82 Volumes.zip",
    "sourceArchiveSha256": "9796bec477cbe2f8017dda81c7e58260985a13bdda1f934e8eb8d0549c2cada5",
    "sourceVolume": "Peptide Research Articles 008 - AOD-9604 and ARA-290.docx",
    "sourceArticleNumber": 40,
    "contentSha256": "794991a7198b3df61c86c625e0574db31763ec276f1173e3e39d337dbdbd15be",
    "statement": "Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed."
  },
  "scope": "Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend."
}
